This is an unprecedented time. It is the dedication of healthcare workers that will lead us through this crisis. Thank you for everything you do.

      Calc Function

    • Calcs that help predict probability of a diseaseDiagnosis
    • Subcategory of 'Diagnosis' designed to be very sensitiveRule Out
    • Disease is diagnosed: prognosticate to guide treatmentPrognosis
    • Numerical inputs and outputsFormula
    • Med treatment and moreTreatment
    • Suggested protocolsAlgorithm

    Disease

    Select...

    Specialty

    Select...

    Chief Complaint

    Select...

    Organ System

    Select...

    Patent Pending

    Glasgow Prognostic Score (GPS) for Cancer Outcomes

    Provides cancer prognosis based on serum biomarkers.

    INSTRUCTIONS

    Note: We recommend the Modified Glasgow Prognostic Score over this original version.
    When to Use
    Pearls/Pitfalls
    Why Use

    Patients with known cancer.

    • The Glasgow Prognostic Score (GPS) has been evaluated across numerous different cancer cohorts and suggests incrementally worsening prognosis with increasing score.
    • Depending upon patient selection, stage, cancer and other factors the resulting survival numbers vary widely.
    • The modified GPS uses the same parameters as the original GPS (CRP and albumin), but weighs the inflammatory component more heavily; i.e., patients with low albumin are still assigned a score of 0 even if CRP is elevated. The modified GPS was shown to have better correlation with survival (in colon and rectal cancer from the original paper, and in other cancers from the validation papers).

    Multiple studies suggest significantly worse outcome in multiple types of cancer, including “increased weight loss, poor performance status, increased comorbidity, increased pro-inflammatory and angiogenic cytokines and complications on treatment.” (McMillan DC 2013)

    CRP ≤10 mg/L
    CRP >10 mg/L
    Albumin <3.5 g/dL (35 g/L)
    Albumin ≥3.5 g/dL (35 g/L)

    Result:

    Please fill out required fields.

    Next Steps
    Evidence
    Creator Insights
    Dr. Donald McMillan

    About the Creator

    Donald McMillan, MD, is a professor of surgical science at the University of Glasgow and an associate academic at the Institute of Cancer Sciences. His research focuses on systemic inflammatory response in weight loss and poor physical function, quality of life and survival of cancer patients.

    To view Dr. Donald McMillan's publications, visit PubMed

    About the Creator
    Dr. Donald McMillan